WO2019224188A1 - Stérol acyltransférases modifiées - Google Patents

Stérol acyltransférases modifiées Download PDF

Info

Publication number
WO2019224188A1
WO2019224188A1 PCT/EP2019/063078 EP2019063078W WO2019224188A1 WO 2019224188 A1 WO2019224188 A1 WO 2019224188A1 EP 2019063078 W EP2019063078 W EP 2019063078W WO 2019224188 A1 WO2019224188 A1 WO 2019224188A1
Authority
WO
WIPO (PCT)
Prior art keywords
dhc
sterol
zymosterol
modified
host cell
Prior art date
Application number
PCT/EP2019/063078
Other languages
English (en)
Inventor
Otto Martin LEHMANN
Harald Pichler
Holly STOLTERFOHT
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Priority to EP19729428.3A priority Critical patent/EP3797158A1/fr
Priority to JP2020557266A priority patent/JP2021524733A/ja
Priority to EA202092792A priority patent/EA202092792A1/ru
Priority to BR112020023803-1A priority patent/BR112020023803A2/pt
Priority to CN201980033840.9A priority patent/CN112154205A/zh
Priority to US17/050,639 priority patent/US20210095325A1/en
Publication of WO2019224188A1 publication Critical patent/WO2019224188A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P33/00—Preparation of steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
    • C12Y103/01—Oxidoreductases acting on the CH-CH group of donors (1.3) with NAD+ or NADP+ as acceptor (1.3.1)
    • C12Y103/01072—DELTA24-sterol reductase (1.3.1.72)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01026—Sterol O-acyltransferase (2.3.1.26)

Definitions

  • the present invention is related to modified sterol acyltransferase enzymes with improved activity and/or specificity towards acylation of the vitamin D3 precursor 7-dehydrocholesterol (7-DHC) to be used in biotechnological production of vitamin D3.
  • the invention further relates to a host strain expressing said modified enzymes and their use in a process for production of vitamin D3 or derivatives and/or metabolites thereof.
  • Vitamin D3 (also known as cholecalciferol or calciol) can be synthesized in the skin of mammals from provitamin D3 (also known as 7-dehydrocholesterol or 7- DHC) which is product of cholesterol biosynthesis upon exposure to UV light, whereby 7-DHC is photochemically converted into provitamin D3, which isomerizes at body temperature to the biologically active form vitamin D3.
  • provitamin D3 also known as 7-dehydrocholesterol or 7- DHC
  • 7-DHC 7-dehydrocholesterol or 7- DHC
  • provitamin D3 also known as 7-dehydrocholesterol or 7- DHC
  • 7-DHC 7-dehydrocholesterol
  • provitamin D3 also known as 7-dehydrocholesterol or 7- DHC
  • 7-DHC 7-dehydrocholesterol
  • 25-hydroxyvitamin D3 also known as calcidiol, calcifediol, 25-hydroxycholecalciferol
  • sterols Excessive amounts of sterols, including 7-DHC and precursors thereof, not required in cellular membranes, are toxic to the yeast and are thus stored as steryl esters into intracellular organelles (so-called lipid bodies) from which they can be further isolated.
  • enzymes including action of sterol acyltransferases.
  • ester formation of sterols is mainly carried out by the two sterol acyltransferases Arel p and Are2p.
  • the steryl ester pool which is stored within the lipid bodies is relatively diverse, including but not limited to e.g. esters of ergosterol, zymosterol, lanosterol, lathosterol, cholesta-5,7,24(25)-trienol, or 7-DHC. Since only cholesta-5,7,24(25)-trienol, a precursor for 7-DHC, and not zymosterol can be used for vitamin D3 synthesis, there is a need for either selective storage of specific esters, such as e.g. esters of 7-DHC, into the lipid bodies and/or for increasing the turnover of
  • a particular metabolite which is also in focus of the present invention is 25-hydroxyvitamin D3.
  • host cells such as yeast capable of producing sterols
  • host cells such as yeast capable of producing sterols
  • the present invention is directed to a modified enzyme with sterol acyltransferase activity, i.e. modified sterol acyltransferases, particularly activity of sterol acyltransferase isoform Arel p and/or Are2p, comprising one or more amino acid substitution(s) at (a) position(s) corresponding to residues selected from the group consisting of 11 , 281 , 366, 442, 551 , 554, 572, 624, 626, 627, 636, and combinations thereof in the polypeptide according to SEQ ID NO: 1 , said modified enzyme has increased specificity for 7-DHC over side- products/intermediates including zymosterol and/or increased activity towards ester formation, including esters of 7-DHC.
  • modified sterol acyltransferase activity i.e. modified sterol acyltransferases, particularly activity of sterol acyltransferase isoform Arel p and/or Are2
  • polypeptide according to SEQ ID NO: 1 showing ARE2 activity, including polynucleotides encoding said polypeptide, has been isolated from
  • Saccharomyces cerevisiae The polypeptide according to SEQ ID NO: 3, showing ARE1 activity, including polynucleotides encoding said polypeptide, has been isolated from Saccharomyces cerevisiae.
  • sterol acyltransferase acyltransferase
  • ARE enzyme having acyltransferase activity
  • enzymes [EC 2.3.1.26], i.e. acyltransferases transferring fatty acyl groups from one molecule to another. Such transfer or enzymatic activity can be measured by means known to the skilled person.
  • Sterol acyltransferases have been isolated from different origins, including mammals, yeast or plants. Both ARE1 and ARE2 are capable of acylating sterols such as e.g. zymosterol and/or 7- DHC to the respective esters.
  • a "modified" enzyme i.e. modified acyltransferase
  • Preferred acyltransferase isoforms are Are2p or Arel p.
  • acyltransferase particularly ARE1 and ARE2, as used herein refers to the respective endogenous enzymes not carrying one or more amino acid
  • a host cell carrying a modified sterol acyltransferase activity as defined herein, particularly ARE2 and/or ARE1 comprising one or more amino acid substitution(s) as defined herein is referred to as "modified” host cell.
  • the respective host cell carrying a non-modified sterol acyltransferase activity, i.e. encoding the wild-type ARE2 and/or ARE1 genes, is referred to as "non-modified" host cell.
  • zymosterol As used herein, the terms “zymosterol”, “lanosterol”, “lathosterol”,”cholesta- 5,8,24(25)-trienol”, “cholesta-5,7,24(25)-trienol", or “7-DHC” specifying vitamin D3 intermediates include both the free form and the ester form of said compounds.
  • a sterol mix contains 7-DHC and "side-products" or intermediates, including but not limited to zymosterol, lanosterol, lathosterol, cholesta-5,8,24(25)-trienol, or cholesta-5,7,24(25)-trienol.
  • a "cholesterol-producing yeast” cannot produce ergosterol anymore but cholesterol products, including, but not limited to cholesta- 5,7,24(25)-trienol, cholesta-5,8,24(25)-trienol, cholesta-7,24(25)-dienol, 7-DHC or zymosterol. Particularly, this might be achieved via introduction of erg5erg6 double-knock out.
  • the modification corresponds to a modified activity of sterol acyltransferase 2 and/or 1 , i.e. ARE2 and/or ARE1 activity, comprising amino acid substitution(s), wherein preferably the at least one amino acid substitution at (a) position(s) corresponding to residues selected from the group consisting of 1 1 , 281 , 366, 442, 551 , 554, 572, 624, 626, 627, 636 and combinations thereof in the polypeptide according to SEQ ID NO: 1 corresponds to (an) amino acid substitution(s) of E1 1 and/or L281 and/or D366 and/or I442 and/or H551 and/or H554 and/or F572 and/or F624 and/or L626 and/or G627 and/or C636.
  • ARE2 and/or ARE1 activity comprising amino acid substitution(s), wherein preferably the at least one amino acid substitution at (a) position(s) corresponding to residues selected
  • the modification corresponds to a modified ARE2 activity, even more preferably a modified polypeptide according to SEQ ID NO: 1 , wherein at least one amino acid substitution at (a) position(s) selected from the group consisting of 1 1 , 281 , 366, 442, 551 , 554, 572, 624, 626, 627, 636, and combinations thereof have been introduced.
  • the enzyme having modified ARE2 and/or ARE1 activity are originated from Saccharomyces, such as S. cerevisiae.
  • the modified enzyme as defined herein, in particular modified ARE2 and/or ARE1 activity comprises an amino acid substitution at a position corresponding to residue 1 1 in the polypeptide according to SEQ ID NO: 1 , preferably substitution of glutamic acid by glycine (E1 1 G).
  • the described amino acid substitution at a position corresponding to residue E1 1 G in SEQ ID NO: 1 might be combined with further substitutions as defined herein, i.e.
  • amino acid substitution at a position corresponding to residue E1 1 G in SEQ ID NO: 1 might be combined with further substitution(s), such as amino acid substitution(s) at position(s) corresponding to F624L, G627D, D366V, C636S, and/or I442V in SEQ ID NO: 1 , more preferably are combinations of substitutions corresponding to residues E1 1 G-F624L, E1 1 G-G627D, E1 1 G-D366V-C636S, E1 1 G-D366V-G627D- C636S, E1 1 G-D366V-F624L-C636S, E1 1 G-D366V-I442V-F624L-C636S or E1 1 G- D366V-I442V-G627D-C636S in SEQ ID NO: 1 , with most preferred combinations selected from E1 1 G-D366V-C636S,
  • enzyme specificity could be increased in the range of at least about 3 to 5-times compared to using a non-modified yeast as defined herein.
  • the modified enzyme as defined herein, in particular modified ARE2 and/or ARE1 activity comprises an amino acid substitution at a position corresponding to residue 281 in the polypeptide according to SEQ ID NO: 1 , preferably substitution of leucine by isoleucine (L281 I).
  • L281 I isoleucine
  • the described amino acid substitution at a position corresponding to residue L281 I in SEQ ID NO: 1 might be combined with further substitutions as defined herein, i.e.
  • the modified enzyme as defined herein, in particular modified ARE2 and/or ARE1 activity comprises an amino acid substitution at a position corresponding to residue 366 in the polypeptide according to SEQ ID NO: 1 , preferably substitution of aspartic acid by valine (D366V).
  • D366V aspartic acid by valine
  • the modified enzyme as defined herein in particular modified ARE2 and/or ARE1 activity, comprises an amino acid substitution at a position corresponding to residue 442 in the polypeptide according to SEQ ID NO: 1 , preferably substitution of isoleucine by valine (I442V).
  • the described amino acid substitution at a position corresponding to residue I442V in SEQ ID NO: 1 might be combined with further substitutions as defined herein, i.e.
  • amino acid substitution at a position corresponding to residue I442V in SEQ ID NO: 1 might be combined with further substitutions, such as amino acid substitutions at position(s) corresponding to F624L, L626F and/or G627D in SEQ ID NO: 1 , more preferably are combinations of substitutions corresponding to residues I442V- L626F, I442V-G627D, I442V-F624L-L626F or I442V-L626F-G627D in SEQ ID NO: 1 , with most preferred combinations selected from I442V-G627D, I442V-F624L- L626F or I442V-L626F-G627D.
  • enzyme specificity could be increased in the range of at least about 2.2 to 4.5-times compared to using a non-modified yeast as defined herein.
  • the modified enzyme as defined herein, in particular modified ARE2 and/or ARE1 activity comprises an amino acid substitution at a position corresponding to residue 551 in the polypeptide according to SEQ ID NO: 1 , preferably substitution of histidine by tyrosine (H551Y).
  • H551Y histidine by tyrosine
  • the described amino acid substitution at a position corresponding to residue H551Y in SEQ ID NO: 1 might be combined with further substitutions as defined herein, i.e.
  • the modified enzyme as defined herein, in particular modified ARE2 and/or ARE1 activity comprises an amino acid substitution at a position corresponding to residue 554 in the polypeptide according to SEQ ID NO: 1 , preferably substitution of histidine by glutamine (H554Q).
  • H554Q histidine by glutamine
  • amino acid substitution at a position corresponding to residue H554Q in SEQ ID NO: 1 might be combined with further substitutions, such as amino acid substitutions at position(s) corresponding to F624L, F572L and/or G627D in SEQ ID NO: 1 , more preferably are combinations of substitutions corresponding to residues H554Q- F572L-F624L or H554Q-F572L-G627D in SEQ ID NO: 1 .
  • the modified enzyme as defined herein in particular modified ARE2 and/or ARE1 activity, comprises an amino acid substitution at a position corresponding to residue 572 in the polypeptide according to SEQ ID NO: 1 , preferably substitution of phenylalanine by leucine (F572L).
  • the described amino acid substitution at a position corresponding to residue F572L in SEQ ID NO: 1 might be combined with further substitutions as defined herein, i.e.
  • the modified enzyme as defined herein, in particular modified ARE2 and/or ARE1 activity comprises an amino acid substitution at a position corresponding to residue 624 in the polypeptide according to SEQ ID NO: 1 , preferably substitution of phenylalanine by leucine (F624L), which corresponds to substitution of F592L in the polypeptide according to SEQ ID NO: 3.
  • F624L phenylalanine by leucine
  • the described amino acid substitution at a position corresponding to residue F624L in SEQ ID NO: 1 might be combined with further substitutions as defined herein, i.e.
  • substitution(s), enzyme specificity could be increased in the range of at least about 3.1 -times compared to using a non-modified yeast as defined herein.
  • the modified enzyme as defined herein, in particular modified ARE2 and/or ARE1 activity comprises an amino acid substitution at a position corresponding to residue 626 in the polypeptide according to SEQ ID NO: 1 , preferably substitution of leucine by phenylalanine (L626F).
  • L626F leucine by phenylalanine
  • the described amino acid substitution at a position corresponding to residue L626F in SEQ ID NO: 1 might be combined with further substitutions as defined herein, i.e.
  • the modified enzyme as defined herein, in particular modified ARE2 and/or ARE1 activity comprises an amino acid substitution at a position corresponding to residue 627 in the polypeptide according to SEQ ID NO:1 , preferably substitution of glycine by aspartic acid (G627D), which corresponds to substitution of G595D in the polypeptide according to SEQ ID NO:3.
  • G627D glycine by aspartic acid
  • the described amino acid substitution at a position corresponding to residue G627D in SEQ ID NO:1 might be combined with further substitutions as defined herein, i.e.
  • enzyme specificity could be increased in the range of at least about 2.2-times compared to using a non-modified yeast as defined herein.
  • the modified enzyme as defined herein, in particular modified ARE2 and/or ARE1 activity comprises an amino acid substitution at a position corresponding to residue 636 in the polypeptide according to SEQ ID NO:1 , preferably substitution of cystine by serine (C636S).
  • C636S cystine by serine
  • the described amino acid substitution at a position corresponding to residue C636S in SEQ ID NO:1 might be combined with further substitutions as defined herein, i.e.
  • a modified sterol acyltransferase according to the present invention such as e.g. ARE2 and/or ARE1 , preferably comprises at least one amino acid
  • a modified sterol acyltransferase according to another embodiment of the present invention preferably comprises at least one amino acid substitution on a position corresponding to G627D in the polypeptide according to SEQ ID NO: 1 , leading to an enzyme specificity of more than 4.
  • the activity of ARE2 and/or ARE1 is modified. This might be achieved by, e.g. introducing (a) mutation(s) into the endogenous gene(s) coding for ARE2 and/or ARE1 , i.e. amino acid substitution(s) on one or more positions as described herein.
  • the skilled person knows how to genetically manipulate a yeast cell resulting in modification of ARE2 and/or ARE1 activity. These genetic manipulations include, but are not limited to, e.g. gene replacement, gene amplification, gene disruption, transfection, transformation using plasmids, viruses, or other vectors.
  • mutagenesis may be performed in different ways, such as for instance by random or side- directed mutagenesis, physical damage caused by agents such as for instance radiation, chemical treatment, or insertion of a genetic element.
  • agents such as for instance radiation, chemical treatment, or insertion of a genetic element.
  • the skilled person knows how to introduce mutations.
  • the present invention is particularly directed to the use of such modified ARE2 and/or ARE1 enzymes as defined herein in a process for production of 7-DHC, an intermediate for vitamin D3.
  • the modified enzymes of the present invention are introduced and/or expressed in a suitable host cell, such as yeast, preferably sterol-producing yeast, in particular cholesterol-producing yeast cell, such as selected from Saccharomyces cerevisiae, Schizosaccharomyces spp., Pichia spp., Klyuveromyces spp., Hansenula spp. or Yarrowia lipolytica, preferably S. cerevisiae.
  • the modified host is used for production of 7-DHC, which might be further converted into vitamin D3 and/or 25-hydroxyvitamin D3.
  • a suitable host cell might be further modified to further increase production of 7-DHC, an important intermediate towards biosynthesis of vitamin D3, and/or reduce accumulation of side-products.
  • the invention is directed to a yeast strain having modified ARE2 and/or ARE1 activity and furthermore wherein ERG5 and ERG6 are inactivated.
  • the yeast cell might be further modified via expression of a heterologous enzyme having C24-reductase activity, particularly selected from EC 1 .3.1 .72, such as a heterologous C24-reductase that is active on cholesta- 7,24-dienol, zymosterol, or trienol (e.g.
  • cholesta-5,7,25-trienol preferably a plant or vertebrate sterol A24-reductase, more preferably from vertebrate source, even more preferably from human, pig, dog, mouse, rat, horse, Danio rerio or any known source, as long as it can be expressed within said yeast cell.
  • the sterol A24-reductase is selected from Danio rerio, rat or human.
  • the sequences expressing said sterol A24-reductase enzymes are publicly available, including but not limited to Um ' ProtKB/Swiss-Prot reference Q15392, Q60HC5, Q8VCH6, Q5BQE6, Q39085 or P93472 (see e.g. W02003064650).
  • the host cell according to the present invention might be further modified via introduction of homologs of endogenous enzymes involved in biosynthesis of 7-DHC, such as e.g. C5-sterol desaturase (ERG3) and/or C8-sterol isomerase (ERG2), resulting in increased specificity and/or productivity of 7-DHC with reduced accumulation of side-products or vitamin D3 intermediates, including but not limited to including zymosterol, lanosterol and/or lathosterol.
  • endogenous enzymes involved in biosynthesis of 7-DHC such as e.g. C5-sterol desaturase (ERG3) and/or C8-sterol isomerase (ERG2)
  • the invention relates to a process for improving a host cell towards production of 7-DHC, wherein a modified host cell as defined herein, i.e. modified via introduction of one or more amino acid substitutions in sterol acyltransferases ARE2 and/or ARE1 as defined herein, in particular a cholesterol-producing yeast cell, preferably a yeast cell in which ERG5 and ERG6 are inactivated and wherein optionally a heterologous enzyme having C-24- reductase activity as defined herein is expressed, and/or wherein optionally homologs of endogenous ERG2 and/or ERG3 are expressed, wherein the host cell is improved such that the percentage of 7-DHC, in the total amount of sterol produced by said host cell is increased and/or the activity of the host cell towards production of sterols is increased, compared to a non-modified host cell as defined herein.
  • a modified host cell as defined herein i.e. modified via introduction of one or more amino acid substitutions in
  • the present invention is directed to modified sterol acyltransferases, particularly modified ARE2 and/or ARE1 , comprising at least one or more amino acid substitution(s) as defined herein, wherein the specificity of the enzyme is increased compared to the specificity of the non-modified enzymes, leading to higher ratio of 7-DHC to side-products including e.g.
  • the ratio might be increased by at least about 1 .4-times, such as e.g. via introduction of amino acid substitutions
  • corresponding to H554Q in the respective ARE2 and/or ARE1 sequence such as increased by at least 3, such as e.g. via introduction of amino acid substitutions corresponding to E1 1 G-F624L, I442V-G627D, or I442V-F624L-L626F in the respective ARE2 and/or ARE1 sequence, such as increased by at least 4-times, such as e.g. via introduction of amino acid substitutions corresponding to F624L or G627D in the respective ARE2 and/or ARE1 sequence, such as at least 5, 10 or even 12-times or more, such as e.g. via introduction of amino acid substitutions corresponding to H554Q-F572L-G627D or E1 1 G-D366V-I442V-G627D-C636S in the respective ARE2 and/or ARE1 sequence.
  • the present invention is directed to modified sterol acyltransferases, particularly modified ARE2 and/or ARE1 , comprising at least one or more amino acid substitution(s) as defined herein, wherein the activity of the enzyme is increased compared to the activity of the non-modified enzymes, leading to higher overall production of sterols and/or steryl esters, including higher amounts of 7-DHC produced by a suitable host cell carrying such modified sterol acyltransferase.
  • the relative ester formation i.e. ratio of all esters to free 7-DHC might be increased by at least 1 .2-times, such as e.g.
  • the percentage of 7-DHC in the sterol mix could by increased by at least 40%, such as 50, 60, 70,
  • a host cell comprising modified ARE2 and/or ARE1 activity as defined herein is used in a process for production of vitamin D3 precursor 7-DHC.
  • the modified host cell may be cultured in an aqueous medium supplemented with appropriate nutrients under aerobic or anaerobic conditions and as known by the skilled person for the respective cholesterol-producing host cells.
  • cultivation is in the presence of proteins and/or co-factors involved in transfer of electrons, as known in the art.
  • the cultivation/growth of the host cell may be conducted in batch, fed- batch, semi-continuous or continuous mode.
  • vitamin D3 and precursors thereof such as 7-DHC can vary, as it is known to the skilled person. Cultivation and isolation of 7-DHC and other intermediates in production of vitamin D3 is described in e.g.
  • the 7-DHC might be isolated and/or optionally further purified from the sterol mix and might be further converted to vitamin D3 and/or 25-hydroxyvitamin D3 using methods known in the art.
  • ARE1 and "Arel p", “ARE2” and “Are2p”, “ERG5" and “Erg5p”, “ERG6” and “Erg6p” are used interchangeably herein and refer to a polypeptide encoded by the respective genes are1 , are2, erg5, and erg6.
  • the cholesterol-producing yeast cell is modified such that it does show modified activity of ARE2 and/or ARE1 , e.g. carries a modification in either endogenous ARE2, ARE1 or both, leading to modified specificity of ARE2 and/or ARE1 , wherein said modification comprises the introduction of one or more amino acid substitution(s) as defined herein.
  • ERG5 Genes encoding ERG5, ERG6, ARE1 , ARE2, ERG2, ERG3, or sterol A24-reductase (ERG4), cultivation and genetic engineering of the yeast cell as used herein are known and described in e.g. US 7608421 .
  • C-24-reductase or "A24-reductase” are used interchangeably herein.
  • this enzyme is encoded by erg4 and is active on the methyl-group of the carbon atom on position 24. Trienol, which does not exhibit such methyl-group on said position, is therefore not an acceptable substrate for the yeast ERG4.
  • C-8 sterol isomerase isomerase
  • this enzyme is encoded by erg2.
  • yeast this enzyme is encoded by erg2.
  • a preferred ERG2 homolog to be used in a modified host cell according to the present invention is a polypeptide having at least 41%, such as e.g.
  • SEQ ID NO: 5 showing C-8 sterol isomerase activity and including polynucleotides encoding such polypeptide obtainable from Ustilago maydis.
  • 1 or more copies, such as at least 1 , 2, 3, 5, of said ERG2 homolog are expressed in a modified host cell as defined herein.
  • C-5 sterol desaturase "enzyme having C-5 sterol desaturase”, “desaturase” or “ERG3-homolog” are used interchangeably herein and refer to enzymes which are capable of catalyzing the conversion of cholesta-8-enol into cholesta-7,24-dienol and/or cholesta-7-enol into cholesta-5,7,24-trienol and/or 7-DHC. In yeast, this enzyme is encoded by erg3.
  • a preferred ERG3 homolog to be used in a modified host cell according to the present invention is a
  • polypeptide having at least 45% such as e.g. at least 50, 52, 60, 70, 80, 90, 92, 95, 98 or up to 100% identity to SEQ ID NO:7 showing C-5 sterol desaturase activity and including polynucleotides encoding such polynucleotide obtainable from Pichia pastoris or Schizosaccharomyces pombe.
  • 1 or more copies, such as at least 1 , 2, 3, 5, of said ERG3 homolog are expressed in a modified host cell as defined herein.
  • the "relative ester formation” as defined herein is the ratio (all ester/ free 7- DHC)mutant/ (all ester/ free 7-DHC) w t.
  • Enzyme “specificity” as defined herein is the ratio (7-DHC ester/ zymosterol ester ) mu tant/ (7-DHC ester/ zymosterol ester)wt.
  • the “total 7-DHC production” as defined herein is the ratio (total 7- DHQmutant/ (7-DHC)wt ⁇
  • the term "specific activity” or "activity” with regards to enzymes means its catalytic activity, i.e. its ability to catalyze formation of a product from a given substrate.
  • the specific activity defines the amount of substrate consumed and/or product produced in a given time period and per defined amount of protein at a defined temperature.
  • specific activity is expressed in pmol substrate consumed or product formed per min per mg of protein.
  • An enzyme is active, if it performs its catalytic activity in vivo, i.e.
  • organisms such as e.g. microorganisms, fungi, algae or plants also include synonyms or basonyms of such species having the same physiological properties, as defined by the
  • the present invention features the present embodiments:
  • a modified enzyme as defined herein with sterol acyltransferase activity having sterol acyltransferase activity comprising one of more amino acid substitution(s) at (a) position(s) corresponding to residues selected from the group consisting of 11 , 281 , 366, 442, 551 , 554, 572, 624, 626, 627, 636, and combinations thereof in the polypeptide according to SEQ ID NO: 1 , preferably one or more amino acid substitution(s) corresponding to E11G and/or L281 I and/or D366V and/or I442V and/or H551Y and/or H554Q and/or F572L and/or F624L and/or L626F and/or G627D and/or C636S and/or combinations thereof.
  • a host cell preferably a yeast, more preferably a sterol-producing yeast, even more preferably a cholesterol-producing yeast, comprising a modified enzyme as defined herein and according to any of embodiments (1 ), (2), (3), said host cell optionally further comprising one of more amino acid substitution(s) at (a) position(s) corresponding to residues selected from 592 and/or 595 in the polypeptide according to SEQ ID NO:3, preferably substitution corresponding to F592L and/or G595D.
  • the host cell as defined herein and of embodiment (4) used for production of a sterol mix comprising 7-DHC and zymosterol, wherein the ratio of 7-DHC to zymosterol is increased by at least about 1.4-times compared to a host cell wherein expressing a non-modified enzyme.
  • heterologous enzyme selected from EC 1.3.1.72 having sterol D24- reductase activity, preferably wherein the heterologous enzyme is originated from plant or vertebrate, more preferably originated from human, pig, dog, mouse, rat, horse or Danio rerio.
  • zymosterol and 7-DHC comprising cultivating a host cell as defined herein and of one of the embodiments (4), (5) or (6) under suitable conditions and optionally isolating and/or purifying the 7-DHC from the sterol mix or a process for increasing the percentage of 7-DHC in a sterol mix comprising 7-DHC and zymosterol comprising cultivating a host cell as defined herein and of one of the embodiments (4), (5) or (6)under suitable conditions and optionally isolating and/or purifying the 7-DHC from the sterol mix.
  • a process for production of 7-DHC comprising enzymatic conversion of acetyl- CoA into a sterol mix comprising zymosterol and 7-DHC with a host as defined herein and of one of the embodiments (4), (5) or (6), wherein the percentage of 7-DHC in the sterol mix is at least 40%, with optionally further conversion of 7- DHC into vitamin D3 and/or 25-hydroxyvitamin D3.
  • Strains were cultivated for two days with two glucose feedings in flasks without baffles. Data are mean values of 3 independent transformants each cultivated once.
  • Figure 2. HPLC analysis of lipid extracts of ARE2 wild-type strainfWT") and Are2 variants #2 and #1 (see Table 1 ). For further details see legend to Figure 1. Strains were cultivated for four days with one glucose feeding in flasks without baffles. Data are mean values of 2 independent transformants each cultivated once.
  • Figure 9 HPLC analysis of lipid extracts of ARE2 wild-type strainfWT" and Are2 variants #27, #33, #34, #37, and #38 (see Table 1 ). For further details see legend to Figure 1. HPLC analysis according to standard procedure. For further details see text.
  • Saccharomyces cerevisiae acyltransferase 2 (ScAre2) were screened by thin layer chromatography (TLC) for improved 7-DHC content in sterol ester fraction (for wild-type sequences of ARE1 and ARE2 (see sequence listing).
  • the screening method comprises the simultaneous extraction and separation of sterols from cells with slightly digested cell walls. The treated biomass was directly applied on the TLC plate and immersed into the solvent, which did the extraction and separation of sterol containing fractions in one step.
  • the ratio of sterols with conjugated double bonds (as e.g. 7-DHC) was set into relation to sterols without conjugated double bonds by exploiting the different spectrophotometric properties of the compounds with the conjugated double bonds (e.g. ability to quench fluorescence, UV detection).
  • the best variants were re-screened in quintuplicates, sequenced, cultivated in shake flasks and analyzed in biological triplicates by HPLC-UV to determine the sterol and sterol ester compositions.
  • Plasmids containing the best variants were isolated and re-transformed into a cholesta-5,7,24-trienol producing Saccharomyces cerevisiae strain 10A (are1 are2 erg5 erg6::24R; for construction see Example 1 in WO2017108799). Mutations of variants with multiple amino acid exchanges were separated by introducing respective mutation into ARE2 by site-directed mutagenesis (silent mutations were not taken into account) to find out which mutation caused the desired effect. Strains were cultivated and analyzed by HPLC.
  • Main cultures of 50 mL YPD with geneticin were inoculated to OD 6 oo 0.1 in 250 mL shake flasks without baffles and were cultivated for 3 days with 3 times glucose feeding (glucose was added to 2% final concentration after approx.
  • the 200 OD cell pellet was thawed, resuspended in 1 mL zymolyase solution (5 mg/mL zymolyase 20T in 50 mM KPi, pH 7, with 1 M D- sorbitol) and incubated for 15 min at 37° C (750 rpm on thermomixer).
  • the zymolyase solution was removed after centrifugation (2500 x g, 5 min) and 3.73 mL of absolute EtOH were added to the pellet (resuspended with 1 mL by pipetting up and down carefully, then adding additional 2.73 mL).
  • Lipid extracts were analyzed by HPLC with UV detection at two wavelengths (210 nm and 280 nm). Zymosterol compounds were detected at 210 nm, 7-DHC compounds were quantified at 280 nm.
  • UV detection 210 nm, 280 nm (sterols with conjugated double bonds)
  • Standard mixtures of 7-DHC, zymosterol, cholesteryl acetate and squalene in 3 different concentrations were analyzed as well and standard curves were generated for each substance to calculate the concentration in pg/pL sterol in extract or pg / OD 6 oo.
  • Example 3 Evaluation of ARE2 variants with regards to activity and/or
  • Table 1 B Summary of specificity of Are2 variants based on several independent experiments. The number indicates the x-times increase in the percentage of 7- DHC compared to the percentage of zymosterol in the sterol mx generated using the indicated amino acids exchange instead of a wild-type ARE2. For more explanation, see text.
  • Table 1 C Summary of total 7-DHC production of Are2 variants based on several independent experiments. The number indicates the x-times increase in the total amount of produced 7-DHC generated using the indicated amino acids exchange instead of a wild-type ARE2. For more explanation, see text.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des enzymes de stérol acyltransférase modifiées ayant une activité et/ou une spécificité améliorées vis-à-vis de l'acylation du précurseur de vitamine D3 7-déshydrocholestérol (7-DHC) à utiliser dans la production biotechnologique de vitamine D3. L'invention concerne en outre une souche hôte exprimant lesdites enzymes modifiées et leur utilisation dans un procédé de production de vitamine D3 ou de dérivés et/ou de métabolites de celle-ci.
PCT/EP2019/063078 2018-05-22 2019-05-21 Stérol acyltransférases modifiées WO2019224188A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP19729428.3A EP3797158A1 (fr) 2018-05-22 2019-05-21 Stérol acyltransférases modifiées
JP2020557266A JP2021524733A (ja) 2018-05-22 2019-05-21 修飾ステロールアシルトランスフェラーゼ
EA202092792A EA202092792A1 (ru) 2018-05-22 2019-05-21 Модифицированные стерол-ацилтрансферазы
BR112020023803-1A BR112020023803A2 (pt) 2018-05-22 2019-05-21 esterol aciltransferases modificadas
CN201980033840.9A CN112154205A (zh) 2018-05-22 2019-05-21 经修饰的甾醇酰基转移酶
US17/050,639 US20210095325A1 (en) 2018-05-22 2019-05-21 Modified sterol acyltransferases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH00628/18 2018-05-22
CH6282018 2018-05-22

Publications (1)

Publication Number Publication Date
WO2019224188A1 true WO2019224188A1 (fr) 2019-11-28

Family

ID=67003440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/063078 WO2019224188A1 (fr) 2018-05-22 2019-05-21 Stérol acyltransférases modifiées

Country Status (7)

Country Link
US (1) US20210095325A1 (fr)
EP (1) EP3797158A1 (fr)
JP (1) JP2021524733A (fr)
CN (1) CN112154205A (fr)
BR (1) BR112020023803A2 (fr)
EA (1) EA202092792A1 (fr)
WO (1) WO2019224188A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064650A1 (fr) 2002-01-29 2003-08-07 Basf Aktiengesellschaft Procede de production de 7-dehydrocholesterol et/ou de ses produits intermediaires et/ou secondaires biosynthetiques dans des organismes transgeniques
WO2011067144A1 (fr) 2009-12-03 2011-06-09 Dsm Ip Assets B.V. Production de stérols de non-levures par une levure
WO2017108799A1 (fr) 2015-12-23 2017-06-29 Dsm Ip Assets B.V. Production de stérols dans une levure modifiée

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064650A1 (fr) 2002-01-29 2003-08-07 Basf Aktiengesellschaft Procede de production de 7-dehydrocholesterol et/ou de ses produits intermediaires et/ou secondaires biosynthetiques dans des organismes transgeniques
US7608421B2 (en) 2002-01-29 2009-10-27 Organobalance Gmbh Method for the production of 7-dehydrocholesterol and/or the biosynthetic intermediate or subsequent products thereof in transgenic organisms
WO2011067144A1 (fr) 2009-12-03 2011-06-09 Dsm Ip Assets B.V. Production de stérols de non-levures par une levure
WO2017108799A1 (fr) 2015-12-23 2017-06-29 Dsm Ip Assets B.V. Production de stérols dans une levure modifiée

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAGMAR ZWEYTICK ET AL: "Contribution of Are1p and Are2p to steryl ester synthesis in the yeast Saccharomyces cerevisiae", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 267, no. 4, 1 February 2000 (2000-02-01), pages 1075 - 1082, XP055059359, ISSN: 0014-2956, DOI: 10.1046/j.1432-1327.2000.01103.x *
WRIESSNEGGER TAMARA ET AL: "Yeast metabolic engineering - Targeting sterol metabolism and terpenoid forma", PROGRESS IN LIPID RESEARCH, PERGAMON PRESS, PARIS, FR, vol. 52, no. 3, 6 April 2013 (2013-04-06), pages 277 - 293, XP028553555, ISSN: 0163-7827, DOI: 10.1016/J.PLIPRES.2013.03.001 *
YU C ET AL: "Molecular cloning and characterization of two isoforms of Saccharomyces cerevisiae Acyl-CoA:Sterol Acyltransferase", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 271, no. 39, 27 September 1996 (1996-09-27), pages 24157 - 24163, XP002094336, ISSN: 0021-9258, DOI: 10.1074/JBC.271.39.24157 *

Also Published As

Publication number Publication date
EA202092792A1 (ru) 2021-04-02
BR112020023803A2 (pt) 2021-02-23
EP3797158A1 (fr) 2021-03-31
JP2021524733A (ja) 2021-09-16
CN112154205A (zh) 2020-12-29
US20210095325A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
Zhu et al. Multidimensional engineering of Saccharomyces cerevisiae for efficient synthesis of medium-chain fatty acids
Javed et al. Bacterial lipases: a review on purification and characterization
DE112015003962T5 (de) 3-Hydroxypropionsäure erzeugende rekombinante Hefe und Verfahren zum Herstellen von 3-Hydroxypropionsäure unter Nutzung derselben
WO2003006644A2 (fr) Lipase/acyltransferase
KR20080073780A (ko) 형질 전환 효모를 사용하는 세라미드의 제조 방법
JPWO2017208791A1 (ja) バイオサーファクタント産生組み換え微生物
CN112135905A (zh) C-8甾醇异构化的优化
WO2023032952A1 (fr) Agent enzymatique pour transestérification contenant une lipase en tant que principe actif
EP2702151B1 (fr) Variants de lipase d'ustilaginaceae
US20210095325A1 (en) Modified sterol acyltransferases
EP3750991A1 (fr) Lipase d'interestérification aléatoire
JP7460540B2 (ja) 修飾ステロールアシルトランスフェラーゼ
JP7443657B2 (ja) Ｃ－５ステロール不飽和化の最適化
EA045290B1 (ru) Модифицированные стерол-ацилтрансферазы
US11634718B2 (en) Production of macrocyclic ketones in recombinant hosts
JP5344517B2 (ja) 小胞体局在化シグナル付スフィンゴリピッドδ４−デサチュラーゼを用いた形質転換細胞におけるセラミドの製造方法
CN110462048A (zh) 异佛尔酮的区域选择性羟基化和朝向氧代异佛尔酮的进一步转换
EA045282B1 (ru) Модифицированные стерол-ацилтрансферазы
Dong et al. Metabolic engineering of Saccharomyces cerevisiae for de novo production of odd-numbered medium-chain fatty acids
EA045256B1 (ru) Оптимизация с-5-десатурации стеролов
Johanson et al. Identification of a Candida sp. reductase behind bicyclic exo-alcohol production
EA045880B1 (ru) Оптимизация с-8-изомеризации стеролов
Hodgman A metabolic engineering approach to increase lipid accumulation in yeast grown on glycerol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19729428

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020557266

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020023803

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019729428

Country of ref document: EP

Effective date: 20201222

ENP Entry into the national phase

Ref document number: 112020023803

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20201123